+

WO1999058562A3 - Nouveaux composes - Google Patents

Nouveaux composes Download PDF

Info

Publication number
WO1999058562A3
WO1999058562A3 PCT/EP1999/003262 EP9903262W WO9958562A3 WO 1999058562 A3 WO1999058562 A3 WO 1999058562A3 EP 9903262 W EP9903262 W EP 9903262W WO 9958562 A3 WO9958562 A3 WO 9958562A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel compounds
polypeptides
basb009
prophylactic
diagnostic
Prior art date
Application number
PCT/EP1999/003262
Other languages
English (en)
Other versions
WO1999058562A2 (fr
Inventor
Joelle Thonnard
Original Assignee
Smithkline Beecham Biolog
Joelle Thonnard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog, Joelle Thonnard filed Critical Smithkline Beecham Biolog
Priority to CA002328061A priority Critical patent/CA2328061A1/fr
Priority to AU42601/99A priority patent/AU4260199A/en
Priority to EP99950345A priority patent/EP1086127A1/fr
Publication of WO1999058562A2 publication Critical patent/WO1999058562A2/fr
Publication of WO1999058562A3 publication Critical patent/WO1999058562A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des polypeptides BASB009 et des polynucléotides codant ces polypeptides BASB009, ainsi que des procédés servant à produire ces polypeptides au moyen de techniques de recombinaison. Elle concerne également leurs mises en application diagnostiques, prophylactiques et thérapeutiques.
PCT/EP1999/003262 1998-05-12 1999-05-10 Nouveaux composes WO1999058562A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002328061A CA2328061A1 (fr) 1998-05-12 1999-05-10 Nouveaux composes
AU42601/99A AU4260199A (en) 1998-05-12 1999-05-10 Novel compounds
EP99950345A EP1086127A1 (fr) 1998-05-12 1999-05-10 Nouveaux composes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9810193.4 1998-05-12
GBGB9810193.4A GB9810193D0 (en) 1998-05-12 1998-05-12 Novel compounds

Publications (2)

Publication Number Publication Date
WO1999058562A2 WO1999058562A2 (fr) 1999-11-18
WO1999058562A3 true WO1999058562A3 (fr) 2001-05-17

Family

ID=10831938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003262 WO1999058562A2 (fr) 1998-05-12 1999-05-10 Nouveaux composes

Country Status (5)

Country Link
EP (1) EP1086127A1 (fr)
AU (1) AU4260199A (fr)
CA (1) CA2328061A1 (fr)
GB (1) GB9810193D0 (fr)
WO (1) WO1999058562A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768662A2 (fr) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
CA2571421A1 (fr) 2004-06-24 2006-01-05 Nicholas Valiante Composes utilises pour l'immunopotentialisation
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
EP1969001A2 (fr) 2005-11-22 2008-09-17 Novartis Vaccines and Diagnostics, Inc. Antigènes de norovirus et de sapovirus
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
EP2357184B1 (fr) 2006-03-23 2015-02-25 Novartis AG Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
CA2699513C (fr) 2007-09-12 2018-03-13 Novartis Ag Antigenes mutants gas57 et anticorps gas57
JP5656642B2 (ja) 2007-12-21 2015-01-21 ノバルティス アーゲー ストレプトリシンｏの変異体形態
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
CA2749367A1 (fr) 2009-01-12 2010-07-15 Novartis Ag Antigenes a domaines cna_b dans des vaccins contre des bacteries a gram positif
WO2010144734A1 (fr) 2009-06-10 2010-12-16 Novartis Ag Vaccins contenant de la benzonaphtyridine
WO2011008400A2 (fr) 2009-06-16 2011-01-20 Novartis Ag Dosages haut débit de bactéricides opsoniques et dépendant d'anticorps à médiation par le complément
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
DK2459216T3 (da) 2009-09-02 2013-12-09 Novartis Ag Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
WO2011057148A1 (fr) 2009-11-05 2011-05-12 Irm Llc Composés et compositions permettant de moduler l'activité des tlr-7
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
KR101853513B1 (ko) 2010-03-23 2018-04-30 노파르티스 아게 감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 ｔｌｒ2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2950819B1 (fr) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Administration intradermique de compositions immunologiques comprenant des agonistes des récepteurs de type toll
EP3752182B1 (fr) 2018-02-12 2024-05-15 Inimmune Corporation Ligands du récepteur de type toll
CA3198876A1 (fr) 2020-11-04 2022-05-12 Eligo Bioscience Phages recombinants de cutibacterium acnes, leur procede de production et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009025A1 (fr) * 1993-09-29 1995-04-06 The Research Foundation Of State University Of New York VACCIN CONTRE $i(BRANHAMELLA CATARRHALIS)
WO1995031215A1 (fr) * 1994-05-17 1995-11-23 The Research Foundation Of State University Of New York VACCIN CONTRE $i(MORAXELLA CATARRHALIS)
WO1997041731A1 (fr) * 1996-05-03 1997-11-13 Antex Biologics, Inc. Polypeptide de la proteine-106 de la membrane externe de moraxella catarrhalis, sa sequence genetique et son utilisation
WO1998006432A1 (fr) * 1996-08-16 1998-02-19 The Research Foundation Of State University Of New York Proteine b1 de la membrane externe de moraxella catarrhalis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009025A1 (fr) * 1993-09-29 1995-04-06 The Research Foundation Of State University Of New York VACCIN CONTRE $i(BRANHAMELLA CATARRHALIS)
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
WO1995031215A1 (fr) * 1994-05-17 1995-11-23 The Research Foundation Of State University Of New York VACCIN CONTRE $i(MORAXELLA CATARRHALIS)
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
WO1997041731A1 (fr) * 1996-05-03 1997-11-13 Antex Biologics, Inc. Polypeptide de la proteine-106 de la membrane externe de moraxella catarrhalis, sa sequence genetique et son utilisation
WO1998006432A1 (fr) * 1996-08-16 1998-02-19 The Research Foundation Of State University Of New York Proteine b1 de la membrane externe de moraxella catarrhalis

Also Published As

Publication number Publication date
AU4260199A (en) 1999-11-29
WO1999058562A2 (fr) 1999-11-18
EP1086127A1 (fr) 2001-03-28
GB9810193D0 (en) 1998-07-08
CA2328061A1 (fr) 1999-11-18

Similar Documents

Publication Publication Date Title
WO1999058562A3 (fr) Nouveaux composes
GB9810276D0 (en) Novel compounds
WO1999055873A3 (fr) Polynucleotide(s) et polypeptides basb006 isoles a partir de neisseria meningites
GB9820003D0 (en) Novel compounds
AU3164600A (en) Novel compounds
GB9809683D0 (en) Novel compounds
AU4504999A (en) Novel compounds
GB9810285D0 (en) Novel compounds
GB9812440D0 (en) Novel compounds
WO2002030971A3 (fr) Nouveaux composes
AU4567300A (en) Novel compounds
WO2002034768A3 (fr) Nouveaux composes
EP2374889A3 (fr) Nouveaux composés
GB9918208D0 (en) Novel compounds
WO2002034772A3 (fr) Nouveaux composes
GB0025170D0 (en) Novel compounds
WO2003010195A3 (fr) Nouveaux composes
AU6832300A (en) Novel compounds
GB9918302D0 (en) Novel compounds
WO2002030967A3 (fr) Nouveaux composes
AU6568800A (en) Novel compounds
WO1999058682A3 (fr) Composes derives de moraxella catarrhalis
WO2002046215A3 (fr) Nouveaux composes
AU6439700A (en) Novel compounds
AU1383901A (en) Novel compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2328061

Country of ref document: CA

Ref country code: CA

Ref document number: 2328061

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999950345

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999950345

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09700335

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999950345

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载